Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin

Hans-Willi M. Breuer, Abteilung für Innere Medizin, St. Carolus-Krankenhaus Görlitz, Carolusstr. 212, 02827 Görlitz, Germany 

Curr Med Res Opin. 2001;17(1):60-73. 

In This Article

Key Messages

  • Hypertriglyceridemia is an independent risk factor for CHD.

  • Reduction in TG levels has been shown to reduce the incidence of coronary events.

  • Cerivastatin achieves substantial reductions in TG of up to 43%.

  • Cerivastatin 0.4 mg and 0.8 mg produced similar reductions in TG compared to atorvastatin 10 mg and 20 mg.

  • 83% of patients treated with atorvastatin 20 mg and 95% of patients overall, treated with cerivastatin 0.8 mg, reached NCEP target LDLC levels.

  • Both atorvastatin and cerivastatin are well tolerated, with similar safety profiles.

  • Combined statin + fibrate therapy may be the most effective treatment for combined dyslipidemias in diabetic patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: